Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Carter’s ( (CRI) ) has provided an update.
On August 14, 2025, Carter’s, Inc. announced a quarterly dividend of $0.25 per share, payable on September 12, 2025, to shareholders of record as of August 26, 2025. This decision reflects the company’s commitment to returning value to its shareholders and is subject to future business conditions and financial performance, as determined by the Board of Directors.
The most recent analyst rating on (CRI) stock is a Hold with a $49.00 price target. To see the full list of analyst forecasts on Carter’s stock, see the CRI Stock Forecast page.
Spark’s Take on CRI Stock
According to Spark, TipRanks’ AI Analyst, CRI is a Neutral.
Carter’s overall stock score is driven by a combination of financial challenges and attractive valuation. While the company faces significant hurdles in profitability and cash flow, its low P/E ratio and high dividend yield offer potential value. Technical indicators suggest caution, and the earnings call highlights both opportunities and risks, particularly from tariffs and expenses.
To see Spark’s full report on CRI stock, click here.
More about Carter’s
Carter’s, Inc. is North America’s largest and most-enduring apparel company exclusively for babies and young children. Its core brands, Carter’s and OshKosh B’gosh, are iconic and trusted names in the sector, sold through over 1,000 company-owned stores in the United States, Canada, and Mexico, as well as online. Carter’s is also the largest supplier of baby and young children’s apparel to North America’s biggest retailers, with exclusive brands available at Walmart, Target, and Amazon. The company is headquartered in Atlanta, Georgia.
Average Trading Volume: 1,653,733
Technical Sentiment Signal: Sell
Current Market Cap: $906.4M
See more insights into CRI stock on TipRanks’ Stock Analysis page.

